JAK Inhibitor Treatment for Myelofibrosis May Be Associated With Development of Aggressive Lymphomas
Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas. They also speculate that screening for a preexisting B-cell clone before starting therapy may help prevent this side effect and potentially save lives, according to a study by Porpaczy et al in Blood.
One of three disorders that falls under the umbrella of myeloproliferative neoplasms is myelofibrosis, a rare bone marrow cancer in which too many blood cells are produced, leading to scarring and hardening inside the bone marrow. The exact cause of myelofibrosis is not known, but it has been linked to the JAK2 gene, which controls the production of blood cells. Doctors treat the condition with medications designed to target or inhibit the action of this gene when it is faulty. Though not a cure, JAK inhibitors provide effective symptom relief, said study coauthor Heinz Gisslinger, MD, of the Medical University of Vienna in Austria. “However, we started noticing sporadic cases of lymphomas developing in patients being treated for myeloproliferative neoplasms, and we wanted to know if this phenomenon was connected to treatment.”
Study Findings
To test this hypothesis, investigators assessed 626 patients receiving treatment for myeloproliferative neoplasms at the Medical University of Vienna. They identified 69 patients with myelofibrosis who were being treated with JAK inhibitors. Of those, 4 (5.8%) developed lymphomas. In comparison, they found that of the 557 patients who did not receive JAK inhibitors, only 2 (0.36%) developed lymphomas. That amounts to a 16-fold increased risk for aggressive B-cell lymphoma in patients receiving JAK inhibitors, said study coauthor Ulrich Jäger, MD, of the Medical University of Vienna.
In samples taken from the patients with myelofibrosis, investigators found a preexisting B-cell clone in the bone marrow in 3 of the 4 patients who later developed lymphoma. Further investigation suggested this clone later transformed into lymphoma. The investigators also demonstrated an association between JAK inhibition and an increased frequency of aggressive B-cell lymphomas in mouse models.
“By replicating this link between this B-cell clone and aggressive lymphoma, we hope to speed the discovery of an alternative therapy for myelofibrosis,” said study coauthor Veronica Sexl, MD, of the University of Veterinary Medicine, Vienna. “These findings are going to be valuable in clinical care.”
“We determined that patients with this preexisting B-cell clone in their bone marrow are most at risk for developing aggressive lymphoma,” said Dr. Jäger. “We also know that up to 16% of people with myelofibrosis have immunoglobulin gene rearrangements like this B-cell clone. Therefore, our findings suggest that all patients with myelofibrosis should be tested for such gene rearrangements before being prescribed JAK inhibitors to treat their disease.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
